These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3480326)

  • 1. [Clinical study of CA15-3 in human breast cancer].
    Nihei M; Nomizu T; Tsuchiya A; Abe R
    Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):987-95. PubMed ID: 3480326
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
    Fuith LC; Artner-Dworzak E; Schröcksnadel H; Müller-Holzner E; Daxenbichler G; Heim K
    Gynakol Rundsch; 1989; 29 Suppl 2():397-9. PubMed ID: 2613061
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of tumor marker CA15-3 in breast cancer].
    Kikuchi K; Uematsu Y; Takada Y; Kurihara E; Suito T; Fujisaki M; Takahashi R; Tamura T
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3095-100. PubMed ID: 3479052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preliminary experience with BCM-IMx as a pretreatment marker of breast tumors].
    Fernández Llana B; Fernández Fernández M; Suárez B; Allende MT
    Rev Clin Esp; 1992 Mar; 190(4):209. PubMed ID: 1589619
    [No Abstract]   [Full Text] [Related]  

  • 5. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y; Imoto S; Kasakura S
    Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer].
    Engel K; Schmid H; Hanke J; Kaufmann M; Müller A
    Geburtshilfe Frauenheilkd; 1988 May; 48(5):309-12. PubMed ID: 3165077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor markers in breast cancer].
    Inaji H; Komoike Y; Motomura K; Koyama H
    Nihon Rinsho; 2000 Apr; 58 Suppl():140-5. PubMed ID: 11025987
    [No Abstract]   [Full Text] [Related]  

  • 9. Circulating tumor markers in breast cancer.
    Tondini C; Hayes DF; Kufe DW
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):653-74. PubMed ID: 2691493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical value of a cancer antigen CA15-3 as a tumor associated antigen in breast carcinoma].
    Hiramoto Y; Tamada R; Sugimachi K; Nomura Y
    Rinsho Byori; 1986 Sep; 34(9):1049-52. PubMed ID: 3467107
    [No Abstract]   [Full Text] [Related]  

  • 11. [General and specific laboratory parameters within the scope of tumor after-care in gynecologic malignancies and breast cancer].
    Kreienberg R
    Gynakologe; 1989 Feb; 22(1):55-62. PubMed ID: 2653979
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
    Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
    Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The pre- and postoperative and follow-up use of the tumor markers MCA, CA-125 and CA-19-9].
    Zanon C; Alluminio P; Margarita V; Sottimano C; Giuliani F; Neri G; Ballario F
    Minerva Chir; 1992 Jan; 47(1-2):27-30. PubMed ID: 1553049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CA15-3 tumor marker in early detection of breast cancer].
    Roisman I; Shiloni E; Lifshiz I; Shoshani D; Saphir D; Honigman I; Livni N; Sherman Y; Papo O; Durst AL
    Harefuah; 1992 Feb; 122(4):213-8. PubMed ID: 1563679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of CA15/3 serum levels in breast cancer patients.
    Gion M; Mione R; Dittadi R; Fasan S; Pallini A; Bruscagnin G
    J Nucl Med Allied Sci; 1986; 30(1):29-36. PubMed ID: 3462353
    [No Abstract]   [Full Text] [Related]  

  • 17. [MCA and CA 15-3 in the follow-up of patients with breast cancer].
    Hammer J; Track C; Hohenwallner W; Seewald DH; Zoidl JP; Wimmer E
    Strahlenther Onkol; 1992 Feb; 168(2):102-6. PubMed ID: 1542844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
    Cappellari A; Bagarella M; Corradi G
    Boll Ist Sieroter Milan; 1990; 69(1):315-8. PubMed ID: 2102115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CA15-3].
    Inaji H
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():651-3. PubMed ID: 16149603
    [No Abstract]   [Full Text] [Related]  

  • 20. CAM 26 and CAM 29: methodological evaluations and first clinical employment in breast cancer.
    Priolo G; Pecchio F; Rapellino M; Aimo G; Spertino F; Pepe C
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):21-3. PubMed ID: 2092121
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.